Annual Full Year Report - My Estimate figuresApart from the cash...

Annual Full Year Report - My Estimate figures



Apart from the cash receipts - the other main items in operating costs I think can influence the bottom line
* salary
* share based payments
* tax benefits.

O = Projected increase in salary to more sale staff.
- = share based payments - should reduce their monetary paid - sp performance has been poor.
they need to stop giving options to their executive to buy at 3c /6c. RHT can buy back some of it shares - and give back to shareholders
<- = tax benefit can influence the bottom line.

Again - these figures are set already and will be past when the results are released.

For sp to move up - Need to look at their Strategy for Growth.


Annual Full Year Report - Strategy for Growth. My Expectation

Search for new distributors in Canada, UK, France, Germany, USA, Oz & NZ.

Hire specialists for each of these countries to build rapport and sign distribution contracts for usage of the AI software suite.

Yes - that will mean increase in salary costs - but who cares when RHT has no debt and sitting on $9m of cash doing crap all in the bank.

Increase the number of distributors from Siemens Healthcare GmbH and 3DR Laboratory Marketplace.

RHT need to capture min 2 new distributors to equate to similar usage size of Siemens and 3DR Lab, thereby increasing its sales receipts at a faster pace.

They also need to maintain the current two distributors but increase their usage of the FerriSmart AI suite and other add on products.

Also, 76% of sales revenue was derived from the usa and canada, with Uk contributing 18%. Therefore, he needs to focus on these 3 countries first. The balance came from europe, australia and middle east.

At June 2020 - RHT only had 55,000 FerriScan analyses usage - which are reimbursed by goverments in UK and Canada - and some private payer in USA.

Therefore I expect the new marketing guy to increase this number to 100,000 in UK and Canada as government are reimbursing for the clients - it will be easier to promote usage.

In the end, the market and investors alike only want to see one thing ---> a jump in cash receipts.

I give the new marketing guy 6 months to get himself in order and start signing contracts and establishing new networks.

The market - i think will only give him 3months - as he comes already with experiences and network in china and usa experiences.



Not sure - my forecast for the new marketing guy to achieve in the coming years wil be what the market is expecting.



This will equate into the different revenue streams:




The new marketing guy needs to focus on:
* Commerical revenue; and
* Clinical Trails - fees for data analytical services.

I think, if he really has the depth of experiences as mentioned above - I think my projected target is achieveable.

But RHT has never provided actual numbers in their growth strategy - so I dont know how the market will react to words and promises of growth only.